title: Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration--evaluation in a clinical setting.
abstract: BACKGROUND
  To identify risk factors for being a "reduced responder" to ranibizumab treatment in a clinical setting in patients with neovascular age-related macular degeneration.
  
  
  METHODS
  This retrospective study included 165 eyes of 165 consecutive patients with choroidal neovascularisation secondary to neovascular, age-related macular degeneration. Eyes were treated with three intravitreal injections of ranibizumab, followed by PRN (pro re nata) dosing thereafter. All patients were reevaluated every four weeks and then followed for six months. Reduced responders were defined as patients with a loss in visual acuity of at least 1 visual acuity line at the last follow-up and/or persistent intraretinal or subretinal fluid or detectable choroidal neovascularisation at the last follow-up, compared to baseline.
  
  
  RESULTS
  Overall, 58 out of 165 eyes (35.2%) were considered to be reduced responders to treatment at the end of follow-up. The initial CNV size at baseline was correlated with the risk of being a reduced responder at the end of follow-up (p = 0.017).
  
  
  CONCLUSIONS
  We identified the initial lesion size as a predictor for a reduced response to treatment in this study. Patients with a large initial lesion size should be thoroughly informed about the possible poorer response to the intravitreal treatment.
authors.affiliation: Department of Ophthalmology, University Medical Centre, Johannes Gutenberg-University, Langenbeckstr,1, Mainz 55131, Germany. christina.korb@unimedizin-mainz.de.
authors.forename: Christina
authors.initials: C
authors.lastname: Korb
authors.forename: Isabella
authors.initials: I
authors.lastname: Zwiener
authors.forename: Katrin
authors.initials: K
authors.lastname: Lorenz
authors.forename: Alireza
authors.initials: A
authors.lastname: Mirshahi
authors.forename: Norbert
authors.initials: N
authors.lastname: Pfeiffer
authors.forename: Bernhard
authors.initials: B
authors.lastname: Stoffelns
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab